+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metabolic Disorders Therapeutics Market Research Report by Disease Type (Diabetes, Hypercholesterolemia, and Lysosomal Storage Disease), Product, Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2027 - Cumulative Impact of COVID-19

  • ID: 4968659
  • Report
  • April 2022
  • Region: Global
  • 189 Pages
  • 360iResearch™
UP TO OFF until Dec 31st 2022

FEATURED COMPANIES

  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon
The Global Metabolic Disorders Therapeutics Market size was estimated at USD 52.06 billion in 2021, USD 56.51 billion in 2022, and is projected to grow at a Compound Annual Growth Rate (CAGR) of 8.72% to reach USD 86.00 billion by 2027.



Market Statistics:


The report provides market sizing and forecast across five major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:


This research report categorizes the Metabolic Disorders Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Disease Type, the market was studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity.
  • Based on Product, the market was studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19:


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Cumulative Impact of 2022 Russia Ukraine Conflict:


We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.

This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Metabolic Disorders Therapeutics market considering the current update on the conflict and its global response.

Competitive Strategic Window:


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Metabolic Disorders Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles:


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Metabolic Disorders Therapeutics Market, including Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, Eli Lily, Merck, Novo Nordisk, and Sanofi.

The report provides insights on the following pointers:


1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:


1. What is the market size and forecast of the Global Metabolic Disorders Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Metabolic Disorders Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Metabolic Disorders Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Metabolic Disorders Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Metabolic Disorders Therapeutics Market?
6. What is the market share of the leading vendors in the Global Metabolic Disorders Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Metabolic Disorders Therapeutics Market?
Frequently Asked Questions about the Global Metabolic Disorders Therapeutics Market

What is the estimated value of the Global Metabolic Disorders Therapeutics Market?

The Global Metabolic Disorders Therapeutics Market was estimated to be valued at $52.1 Billion in 2021.

What is the growth rate of the Global Metabolic Disorders Therapeutics Market?

The growth rate of the Global Metabolic Disorders Therapeutics Market is 8.7%, with an estimated value of $86.0 Billion by 2027.

What is the forecasted size of the Global Metabolic Disorders Therapeutics Market?

The Global Metabolic Disorders Therapeutics Market is estimated to be worth $86.0 Billion by 2027.

Who are the key companies in the Global Metabolic Disorders Therapeutics Market?

Key companies in the Global Metabolic Disorders Therapeutics Market include Abbvie, Actelion Pharmaceuticals, Amicus Therapeutics, Arena Pharmaceuticals, Astazeneca Plc, Biocon, Eli Lily, Merck and Sanofi.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing awareness regarding the treatment of metabolic disorders
5.1.1.2. Surge in demand for one-time therapies for metabolic disorders
5.1.1.3. Increase in the cases of diabetes
5.1.2. Restraints
5.1.2.1. Accessibility to the alternative option for the treatment of metabolic disorders
5.1.3. Opportunities
5.1.3.1. Rise in the funding for the development of novel therapeutic approaches
5.1.3.2. Robust advancement in the technology related to metabolic disorders
5.1.4. Challenges
5.1.4.1. Uncertainty in regulatory policies
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of 2022 Russia Ukraine Conflict
6. Metabolic Disorders Therapeutics Market, by Disease Type
6.1. Introduction
6.2. Diabetes
6.3. Hypercholesterolemia
6.4. Lysosomal Storage Disease
6.5. Obesity
7. Metabolic Disorders Therapeutics Market, by Product
7.1. Introduction
7.2. Globoid Leukodystrophy
7.3. Hepatic Encephalopathy
7.4. Metachromatic Leukodystrophy
8. Americas Metabolic Disorders Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Metabolic Disorders Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
10. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Abbvie
12.2. Actelion Pharmaceuticals
12.3. Amicus Therapeutics
12.4. Arena Pharmaceuticals
12.5. Astazeneca Plc
12.6. Biocon
12.7. Eli Lily
12.8. Merck
12.9. Novo Nordisk
12.10. Sanofi
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing
List of Figures
FIGURE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: DYNAMICS
FIGURE 2. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (%)
FIGURE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2021 VS 2027 (USD BILLION)
FIGURE 4. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2027
FIGURE 5. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, 2019-2027 (USD BILLION)
FIGURE 6. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 7. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, 2019-2027 (USD BILLION)
FIGURE 8. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, 2019-2027 (USD BILLION)
FIGURE 10. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 11. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, 2019-2027 (USD BILLION)
FIGURE 12. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 13. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (%)
FIGURE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2021 VS 2027 (USD BILLION)
FIGURE 15. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2027
FIGURE 16. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, 2019-2027 (USD BILLION)
FIGURE 17. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 18. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, 2019-2027 (USD BILLION)
FIGURE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 20. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, 2019-2027 (USD BILLION)
FIGURE 21. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2021 VS 2027 (USD BILLION)
FIGURE 22. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 23. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 24. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 25. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 26. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 27. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 28. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 29. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 30. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 31. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 32. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 33. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 34. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 35. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 36. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 37. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 38. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 39. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 40. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 41. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 42. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 43. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 44. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 45. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 46. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 47. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 48. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 49. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 50. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 51. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
FIGURE 52. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: FPNV POSITIONING MATRIX
FIGURE 53. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
FIGURE 54. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET, BY TYPE
List of Tables
TABLE 1. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2019-2027 (USD BILLION)
TABLE 4. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2019-2027 (USD BILLION)
TABLE 5. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 6. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY STATE, 2019-2027 (USD BILLION)
TABLE 7. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 8. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 9. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2019-2027 (USD BILLION)
TABLE 10. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY STATE, 2019-2027 (USD BILLION)
TABLE 12. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 13. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 14. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2019-2027 (USD BILLION)
TABLE 15. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 16. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY STATE, 2019-2027 (USD BILLION)
TABLE 17. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 18. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 19. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2019-2027 (USD BILLION)
TABLE 20. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 21. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY STATE, 2019-2027 (USD BILLION)
TABLE 22. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 23. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 24. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2019-2027 (USD BILLION)
TABLE 25. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2019-2027 (USD BILLION)
TABLE 26. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 27. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 28. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 30. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2019-2027 (USD BILLION)
TABLE 31. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 32. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 33. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 34. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 35. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2019-2027 (USD BILLION)
TABLE 36. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 37. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY STATE, 2019-2027 (USD BILLION)
TABLE 38. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 39. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY COUNTRY, 2019-2027 (USD BILLION)
TABLE 40. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 41. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 42. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 43. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 44. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 45. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 46. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 47. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 48. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 49. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 50. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 51. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 52. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 53. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 54. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 55. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 56. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 57. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 58. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 59. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 60. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 61. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 62. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 63. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 64. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 65. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 66. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 67. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 68. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 69. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2019-2027 (USD BILLION)
TABLE 70. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: SCORES
TABLE 71. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: BUSINESS STRATEGY
TABLE 72. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: PRODUCT SATISFACTION
TABLE 73. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: RANKING
TABLE 74. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: SHARE, BY KEY PLAYER, 2021
TABLE 75. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: MERGER & ACQUISITION
TABLE 76. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 77. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 78. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: INVESTMENT & FUNDING
TABLE 79. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 80. GLOBAL METABOLIC DISORDERS THERAPEUTICS MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • Abbvie
  • Actelion Pharmaceuticals
  • Amicus Therapeutics
  • Arena Pharmaceuticals
  • Astazeneca Plc
  • Biocon
  • Eli Lily
  • Merck
  • Novo Nordisk
  • Sanofi
Note: Product cover images may vary from those shown

Loading
LOADING...